Low Dose Statins, Ezetimibe and Nutraceuticals

Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol)

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03277079

Acronym

TACO

Enrollment

100

Registered

2017-09-08

Start date

2017-10-01

Completion date

2018-03-31

Last updated

2017-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery disease, LDL cholesterol, therapeutic target

Brief summary

It remains unknown if the association between moderate to low intensity statin therapy and ezetimibe and nutraceuticals might have a therapeutic role in high-intensity statin intolerant patients

Detailed description

The aim of this study will be to evaluate whether the association between statin and exetimibe vs statin + ezetimibe + nutraceuticals can lead to higher percentage of LDL target achievement

Interventions

DRUGstatin + ezetimibe

Combination of two drugs

DRUGstatin + ezetimibe + Nutraceuticals

Combination of two grus plus nutraceuticals

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with angiographically assessed diagnosis of coronary artery disease

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame	Description
Therapeutic target	Up to 3 months	LDL cholesterol \< 70 mg/dl

Countries

Italy

Contacts

Primary ContactFrancesco Pelliccia, MD

f.pelliccia@mclink.it39064997

Backup ContactGiuseppe Marazzi, MD

marazzig@gmai.com39064997

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026